Drug Profile


Alternative Names: CDDD 1815; HGP 5

Latest Information Update: 07 Oct 1996

Price : $50

At a glance

  • Originator Unknown
  • Developer Pharmos Corporation
  • Class Antiglaucomas
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 07 Oct 1996 Discontinued-II for Glaucoma in USA (Ophthalmic)
  • 15 Jul 1994 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top